Debut in diabetic patients with hepatitis C treatment with ledipasvir/ sofosbuvir (Harvoni®)

Debut in diabetic patients with hepatitis C treatment with ledipasvir/ sofosbuvir (Harvoni®)

Bibliographic Details
Main Authors:	Sergio Vicente-Sánchez, Laura Menéndez Naranjo
Format:	Article
Language:	English
Published:	Grupo Aula Médica 2017-03-01
Series:	Farmacia Hospitalaria
Online Access:	http://www.aulamedica.es/fh/pdf/10674.pdf

Similar Items

Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data.
by: Guo-Feng Chen, et al.
Published: (2016-01-01)

Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade.
by: Albert Do, et al.
Published: (2015-01-01)

Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C
by: Yang CHT, et al.
Published: (2018-07-01)

Treatment with ledipasvir-sofosbuvir for hepatitis C resulting in improvement of lichen planus
by: Umer Ansari, BS, et al.
Published: (2017-01-01)

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.
by: Jona T Stahmeyer, et al.
Published: (2017-01-01)

Autoimmune Hepatitis During Ledipasvir/Sofosbuvir Treatment of Hepatitis C: A Case Report
by: Giovanni Covini, et al.
Published: (2018-10-01)

Daclatasvir/Sofosbuvir versus Ledipasvir/Sofosbuvir in Patients with Hepatitis C Virus Infection Genotypes 1 and 3
by: Narjes Shokatpour, et al.
Published: (2020-06-01)

Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents
by: Jesús Quintero, et al.
Published: (2019-03-01)

Acute Kidney Injury in Patients Undergoing Chronic Hepatitis C Virus Treatment With Ledipasvir/Sofosbuvir
by: Patrick R. Brown, et al.
Published: (2018-10-01)

Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C
by: Naylor PH, et al.
Published: (2017-03-01)

Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
by: Peter Buggisch, et al.
Published: (2019-01-01)

Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients
by: Shih-Jer Hsu, et al.
Published: (2020-03-01)

New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir
by: Resmi Premji MD, et al.
Published: (2015-12-01)

Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
by: Sundaram V, et al.
Published: (2016-06-01)

RESULTS OF THE USE OF SOFOSBUVIR IN COMBINATION WITH LEDIPASVIR OR DACLATASVIR FOR CHRONIC HEPATITIS C TREATMENT IN THE REPUBLIC OF BELARUS
by: S. V. Zhavoronok, et al.
Published: (2018-10-01)

Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients
by: Mohammed A Babatin, et al.
Published: (2019-01-01)

Liver Fibrosis Is Associated With Corrected QT Prolongation During Ledipasvir/Sofosbuvir Treatment for Patients With Chronic Hepatitis C
by: Yuki Tahata, et al.
Published: (2018-08-01)

Ledipasvir/sofosbuvir induced nephrotic syndrome: A challenging case of Hepatitis C management
by: Zaver, Himesh, et al.
Published: (2018)

Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective
by: Nkuize M, et al.
Published: (2016-06-01)

The efficacy and safety of sofosbuvir/ledipasvir therapy in patients on long-term hemodialysis with hepatitis C virus infection
by: G Li Cavoli, et al.
Published: (2018-01-01)

Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study
by: Heidar Sharafi, et al.
Published: (2020-01-01)

Clinical effect and safety of sofosbuvir-ledipasvir regimen in treatment of patients with HCV genotype 6a chronic hepatitis C
by: LI Wei
Published: (2019-03-01)

Successful Treatment of Hepatitis C Virus by Ledipasvir/Sofosbuvir in a Cirrhotic Patient with Sickle Cell Disease and Thalassemia Minor
by: Hassan Al Moussawi, et al.
Published: (2018-10-01)

Eight Weeks of Ledipasvir/Sofosbuvir in Kidney Transplant Recipients With Hepatitis C Genotype 1 Infection
by: Jennifer S. Husson, MD, MPH, et al.
Published: (2017-12-01)

Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis
by: Mohammad Saeid Rezaee-Zavareh, et al.
Published: (2017-03-01)

Ledipasvir and sofosbuvir for treatment of post- renal transplant hepatitis C infection: A case report withreview of literature
by: R Jha, et al.
Published: (2016-01-01)

Treatment of de novo hepatitis C virus-related fibrosing cholestatic hepatitis after orthotopic heart transplantation by ledipasvir and sofosbuvir
by: Chen-Hua Liu
Published: (2017-05-01)

Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection
by: Ahmed OA, et al.
Published: (2018-03-01)

Combinación de ledipasvir/sofosbuvir como tratamiento de la infección crónica por hepatitis C
by: Jesús Quintero, et al.
Published: (2019-03-01)

Outcomes of Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir in Mongolian Population: Successes and Challenges Facing Scale-up of Care
by: Seong Hee Kang, et al.
Published: (2021-01-01)

The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis
by: William Stokes, et al.
Published: (2017-01-01)

An unfortunate failure: multifocal hepatocellular carcinoma in a non-cirrhotic patient with chronic hepatitis C treated with ledipasvir/sofosbuvir
by: Megan Sue Soliman, et al.
Published: (2018-05-01)

Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant
by: Eric M. Yoshida, et al.
Published: (2017-05-01)

Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir/Sofosbuvir Plus Ribavirin Pretransplant
by: Carmen Vinaixa, et al.
Published: (2017-05-01)

Effectiveness and safety of sofosbuvir/ledipasvir ± ribavirin treatment in liver and/or renal transplant patients with chronic hepatitis C: A single-center experience
by: Mete Akin, et al.
Published: (2018-06-01)

Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis
by: Xue Yang, et al.
Published: (2021-07-01)

Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study
by: Catherine A Chappell, MD, et al.
Published: (2020-09-01)

Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment
by: Bashar Aqel, et al.
Published: (2018-09-01)

Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan.
by: Chen-Hua Liu, et al.
Published: (2018-01-01)

Randomized feasibility trial of directly observed versus unobserved hepatitis C treatment with ledipasvir-sofosbuvir among people who inject drugs.
by: Phillip O Coffin, et al.
Published: (2019-01-01)